GE continues slim down with $21bn sale of BioPharma business
GE announced a change of plans regarding its GE Healthcare business, choosing to sell off the BioPharma business for $21.4bn rather than initiate an IPO.
Archives for February 25, 2019
‘Production efficiency’ crucial in ‘battle of biosimilars’
Celltrion Healthcare’s head of medical and marketing outlines how the US biosimilar market is evolving and how manufacturing efficiency could become a key distinguisher from competitors.
Roche buys into gene therapies with $4.8bn Spark acquisition
Roche gains access to Spark’s potential gene therapy treatments for haemophilia to complement its existing portfolio in the space.